Gena Wang

Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported positive interim data from an ongoing Phase...

Editas Medicine Inc (NASDAQ: EDIT) reported third-quarter earnings Tuesday and it failed to meet Wall Street expectations. The Analyst Barclays' Gena Wang. The Rating Wang maintained an Overweight on Editas Medicine, with a price target of $28. (See Wang's track record here.) The...

Juno Therapeutics Inc (NASDAQ: JUNO) opened sharply higher after reporting third-quarter earnings after the close Wednesday. The report highlighted ASH abstracts on JCAR017, a non-Hodgkin lymphoma drug, showing promising efficacy and solid safety in r/r DLBCL, Barclays analyst Gena Wang said...

Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a Positive view, as it expects the outperformance of the sector relative to the S&P 500 to continue in the next 12-18 months. The firm's positive opinion was premised on three factors, namely phase 3...

z,pz.Even as Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a positive view, it was bearish on Cascadian Therapeutics Inc (USA) (NASDAQ: CASC) and Zymeworks Inc (NYSE: ZYME). The firm initiated coverage of Cascadian Therapeutics with an Underweight rating...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares nearly doubled back in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, after conducting a round of due diligence by talking to private payers and other experts, Jefferies analyst Gena Wang...

Following, Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) announcing the termination of a late-stage study of Revusiran, citing mortality imbalance, Jefferies said it strongly believes the issue might be program- or disease-specific rather than being overall technology platform-related. Gena Wang, an...

Following the presentation of KRN23 data by Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Monday, Jefferies noted the longer follow-up data is clinically meaningful, supporting filing for a EU conditional approval by 2016. Elaborating on the data, equity analyst Gena Wang noted that data from the...

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares are up another 4.2 percent in early Tuesday trading following a big 20.6 percent Monday gain. The big move in PTC shares has been driven by the FDA’s accelerated approval of Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Eteplirsen for treatment...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) were down as much as 2 percent in the pre-market hours Tuesday following the U.S. FDA questioning the effectiveness of Translarna in nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC was notified that negative results from both Phase-2b and...

Editor's note: This is an update to a story published earlier on Benzinga. Shares of OvaScience Inc (NASDAQ: OVAS) soared 35 percent Thursday following its announcement on Wednesday that it achieved its 2014 corporate goals. The company is advancing the AUGMENTSM, OvaPrimeSM and OvaTureSM...